Step-by-step guides, research summaries, and treatment overviews β reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory β we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard β not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights β by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
Rare Cancer Treatments
CGP analyses hundreds of genes across multiple alteration types: SNVs, indels, CNAs, gene fusions, MSI, TMB. Critical for rare cancers: RNA-based fusion detection (NTRK, RET, ALK, ROS1, FGFR2 fusions). Chinese NGS: Burning Rock OncoScreen Plus (520-gene, NMPA-approved), Geneseeq ONE (825-gene). Molecular tumour board interpretation at CAMS/FUSCC. T
Pediatric Cancer Advanced Therapy
Dinutuximab (anti-GD2) for high-risk neuroblastoma: proven survival benefit. Checkpoint inhibitors for Hodgkin lymphoma. Blinatumomab (bispecific T-cell engager) for B-ALL. Tumour-agnostic pembrolizumab for MSI-H/TMB-high. Most pediatric tumours are cold β adult checkpoint results dont translate uniformly.
Rare Cancer Treatments
MSI-H/TMB-high rare cancers: strongest checkpoint response (pembrolizumab approved tumour-agnostically). Mesothelioma: nivolumab+ipilimumab first-line standard (CheckMate 743). Merkel cell carcinoma: high checkpoint response. ASPS: ~25% ORR despite low PD-L1. Chinese PD-1 inhibitors (camrelizumab, sintilimab, tislelizumab) at substantially lower co
Stage 4 Cancer
Immunotherapy is not a universal stage 4 cancer treatment -- it is a precisely applicable one. Pembrolizumab is approved for MSI-H/dMMR tumours of any cancer type, TMB-high solid tumours, and multiple specific cancer types. PD-L1 expression, MSI status, and TMB together determine immunotherapy eligibility. Durable complete responses documented in melanoma have been maintained for 5+ years after stopping treatment.
Rare Cancer Treatments
First-line: nivolumab+ipilimumab (CheckMate 743) β superior OS over platinum/pemetrexed for pleural mesothelioma. 5-year survival doubled from 9% to 18%. Chinese domestic checkpoint inhibitors at lower cost. Molecular landscape: BAP1 loss (~60%), NF2 loss (~50%), low TMB. SPHIC proton therapy for localised/post-surgical disease. Peritoneal mesothel
Precision Oncology
Rare cancer patients who have been told that limited options exist should know: the question precision oncology asks is not whether your cancer type has a matched drug, but whether your tumour carries a molecular feature that has a matched drug regardless of cancer type. Tumour-agnostic approvals (MSI-H, NTRK fusions, TMB-high, RET fusions) apply to any solid tumour carrying the feature.
Precision Oncology
Single gene testing answers exactly one question per test. NGS sequences 300-500+ genes simultaneously from the same tissue sample, covering all established alterations plus TMB and MSI in one episode. Sequential single-gene testing in lung cancer -- testing EGFR, then KRAS, then ALK one at a time -- takes weeks, uses significant tissue, and can miss relevant findings if the sequence stops before all targets are checked.
Tumor Therapeutic Vaccines
Key questions to ask about cancer vaccines β by category: Eligibility (Am I a realistic candidate? Has my tumor been sequenced? What is my TMB?), Treatment (Approved or trial? Full regimen including checkpoint inhibitor? Timeline to first dose?), Side effects (Specific combo profile? Symptoms requiring immediate call?), Response (What does responding mean? Response rates in my profile?), Logistics (Visit schedule? Local monitoring possible?), Cost (Total realistic cost? Insurance navigation? Assistance programs?).
Precision Oncology
The questions worth asking about NGS results differ by what is being decided. Before the results appointment: is the testing picture complete (comprehensive NGS, TMB, MSI, RNA sequencing)? During the results appointment: which findings are Tier I? Is there an FDA-approved drug? A tumour-agnostic approval? Currently enrolling basket trials? After: should this case go to a molecular tumour board?
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis β from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres β including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide Β· 8 min
02Second opinion Β· 6 min
03Precision oncology Β· 10 min
04Clinical trials Β· 7 min
05Clinical trials Β· 9 min
06Precision oncology Β· 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β even when the honest answer is harder to hear.
β CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
